Novo Nordisk Shares Plunge 1.51% Following Disappointing CagriSema Trial Results

Market Performance Summary for Novo Nordisk A/S on May 21, 2026

Stock Price Movement

On May 21, 2026, Novo Nordisk A/S (NYSE: NVO) experienced a significant decline in its stock price, closing at $44.39, down from the previous close of $45.07. This represents a decrease of $0.68, or approximately 1.51%. During the trading session, the stock opened at $44.22, reached a high of $44.59, and fell to a low of $43.74, with a total trading volume of approximately 5.13 million shares. This volatility reflects the market's reaction to recent news regarding the company's product performance and competitive landscape.

Key News Influencing Stock Performance

1. CagriSema Trial Results
   The most significant factor impacting Novo Nordisk's stock on this day was the announcement regarding its weight loss drug, CagriSema. The drug failed to meet its trial goals, specifically not achieving non-inferiority compared to Eli Lilly's tirzepatide. CagriSema patients lost about 23% of their body weight over 84 weeks, while those on tirzepatide lost approximately 25.5%. This disappointing outcome has led to a substantial drop in investor confidence, with shares plummeting over 14% in response to the news.
2. Market Outlook
   Following the trial results, Novo Nordisk projected a decline in sales and profits for 2026, estimating a decrease of 5% to 13%. This forecast is attributed to increased competition, particularly from Eli Lilly, and anticipated pricing pressures in the U.S. market. The CEO of Novo Nordisk acknowledged these challenges, indicating that investors should brace for further declines before any potential recovery.
3. Investor Sentiment
   The market reaction was swift, with investor sentiment shifting towards Eli Lilly, whose stock rose by 3.5% in pre-market trading following the news. This shift underscores the competitive pressure that Novo Nordisk faces in the obesity and diabetes treatment markets, particularly as Eli Lilly's tirzepatide has gained a strong foothold.
4. Financial Performance Context
   In the context of its broader financial performance, Novo Nordisk's stock has already seen a nearly 50% decline in value over the past year. This ongoing downward trend has compounded the pressure on the company, making the recent trial results even more detrimental to investor confidence.
5. Competing Products
   The competitive landscape for GLP-1 receptor agonists, which includes Novo Nordisk's Ozempic and Wegovy, is becoming increasingly crowded. The emergence of new products and competitive pricing strategies from rivals is anticipated to further challenge Novo Nordisk's market position and profitability.

Conclusion

The stock performance of Novo Nordisk A/S on May 21, 2026, was heavily influenced by the disappointing results of the CagriSema trial against Eli Lilly's tirzepatide, leading to a significant drop in share price. The company's outlook for 2026 has worsened, and investor sentiment has shifted unfavorably, reflecting concerns over increased competition and potential revenue declines. As the market continues to react to these developments, investors are advised to monitor further announcements and trial results closely.